natgillin/translations-raw huggingface dataset:
In both studies, patients with active disease entered an open-label period (OLP) during which they treated affected lesions with tacrolimus ointment twice daily until improvement had reached a predefined score (Investigator’s Global Assessment [IGA] ≤ 2, i.e. clear, almost clear or mild disease) for a maximum of 6 weeks.
V obeh študijah so bolniki z aktivno boleznijo vstopili v odprto obdobje zdravljenja, med katerim so največ 6 tednov uporabljali mazilo s takrolimusom dvakrat na dan, dokler ni izboljšanje kožnih sprememb doseglo vnaprej opredeljene ocene (IGA - Investigator's Global Assessment – raziskovalčeva globalna ocena ≤ 2, to pomeni, da so spremembe izginile, skoraj izginile ali pa gre za blago bolezen).
In both studies, Revlimid was compared with placebo (a dummy treatment), both taken in combination with dexamethasone.
V obeh študijah so zdravilo Revlimid primerjali s placebom (zdravilom brez zdravilne učinkovine), ki so ju bolniki jemali skupaj z deksametazonom.
In both studies, Tasigna had a similar effect in patients who could not tolerate imatinib and those whose disease had stopped responding to it.
V obeh študijah je imelo zdravilo Tasigna podoben učinek pri bolnikih, ki ne prenašajo imatiniba ali tistih, pri katerih se bolezen nanj več ne odziva.
In both studies, the 10 mg/kg dose of Benlysta was more effective than the 1 mg/kg dose.
V obeh študijah je bil odmerek 10 mg/kg zdravila Benlysta učinkovitejši kot odmerek 1 mg/kg.
In both studies, the baseline demographic and disease-related characteristics were comparable between the lenalidomide/dexamethasone and placebo/dexamethasone groups.
V obeh študijah so bile izhodiščna demografija in značilnosti, povezane z boleznijo, primerljive med skupinama, ki sta prejemali lenalidomid/deksametazon in placebo/deksametazon.
In both studies, the effectiveness of a single injection of Neulasta was compared with multiple daily injections of filgrastim during each of four chemotherapy cycles.
V obeh študijah so primerjali učinkovitost enkratne injekcije zdravila Neulasta z večkratnimi dnevnimi injekcijami filgrastima med vsakim od štirih ciklov kemoterapije.
In both studies, the main measure of effectiveness was based on the number of patients who had blood clots forming in the veins or who died of any cause during the treatment period.
V obeh študijah je bilo glavno merilo učinkovitosti število bolnikov, pri katerih so nastali krvni strdki v venah ali ki so med zdravljenjem umrli zaradi katerega koli razloga.
In both studies, the main measure of effectiveness was how Enurev Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks of treatment.
Glavno merilo učinkovitosti v obeh študijah je bilo izboljšanje forsiranega ekspiracijskega volumna v prvi sekundi (FEV1, največja količina zraka, ki jo oseba lahko izdihne v eni sekundi) po 12 tednih jemanja zdravila.
In both studies, the main measure of effectiveness was how Seebri Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks of treatment.
Glavno merilo učinkovitosti v obeh študijah je bilo izboljšanje forsiranega ekspiracijskega volumna v prvi sekundi (FEV1, največja količina zraka, ki jo oseba lahko izdihne v eni sekundi) po 12 tednih jemanja zdravila.
In both studies, the main measure of effectiveness was how Tovanor Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks of treatment.
Glavno merilo učinkovitosti v obeh študijah je bilo izboljšanje forsiranega ekspiracijskega volumna v prvi sekundi (FEV1, največja količina zraka, ki jo oseba lahko izdihne v eni sekundi) po 12 tednih jemanja zdravila.
In both studies, the main measure of effectiveness was how Ultibro Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
V obeh študijah je bilo glavno merilo učinkovitosti bolnikovo izboljšanje forsiranega ekspiracijskega volumna (FEV1 – največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) po 26 tednih zdravljenja.
In both studies, the main measure of effectiveness was how Ulunar Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
V obeh študijah je bilo glavno merilo učinkovitosti bolnikovo izboljšanje forsiranega ekspiracijskega volumna (FEV1 – največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) po 26 tednih zdravljenja.
In both studies, the main measure of effectiveness was how Xoterna Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
V obeh študijah je bilo glavno merilo učinkovitosti bolnikovo izboljšanje forsiranega ekspiracijskega volumna (FEV1 – največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) po 26 tednih zdravljenja.
In both studies, the main measure of effectiveness was the decline in the functioning of the patients’ lungs over the course of 1 year of treatment, measured by their forced vital capacity (FVC).
Glavno merilo učinkovitosti v obeh študijah je bilo poslabšanje delovanja pljuč pri bolnikih v enem letu zdravljenja, kar so merili z njihovo forsirano vitalno kapaciteto (FVC).
In both studies, the main measure of effectiveness was the number of patients who had a lasting response to treatment.
V obeh študijah je bilo glavno merilo učinkovitosti število bolnikov s trajnim odzivom na zdravljenje.
In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment.
Glavno merilo učinkovitosti v obeh študijah je bilo število bolnikov, katerih krvne preiskave šest mesecev po zaključku zdravljenja niso pokazale nobenih znakov prisotnosti virusa hepatitisa C.
In both studies, the main measure of effectiveness was the number of patients whose disease activity decreased to a certain level after 12 months.
V obeh študijah je bilo glavno merilo učinkovitosti število bolnikov, pri katerih se je po 12 mesecih bolezenska aktivnost zmanjšala na določeno raven.
In both studies, the main measure of effectiveness was the proportion of patients who responded to treatment, i.e. whose GH and IGF-1 levels decreased to pre-defined values (less than 2.5 micrograms/liter for GH or within normal limits for IGF-1).
V obeh študijah je bilo glavno merilo učinkovitosti delež bolnikov, ki so se odzvali na zdravljenje, torej tistih, pri katerih so se ravni GH in IGF-1 zmanjšale na predhodno opredeljene vrednosti (na manj kot 2,5 mikrograma/liter za GH ali na normalne vrednosti za IGF-1).
In both studies, the main measure of effectiveness was therefore the change in the functioning of the patients’ lungs after 72 weeks of treatment, measured by their ‘forced vital capacity’ (FVC).
V obeh študijah je bilo tako glavno merilo učinkovitosti sprememba delovanja pljuč po 72 tednih zdravljenja, ki so jo merili s „forsirano vitalno kapaciteto“ (FVC).
In both studies, the main measures of effectiveness were the levels of haemoglobin during treatment, as well as the dose of epoetin received.
V obeh študijah sta bili glavni merili učinkovitosti raven hemoglobina med zdravljenjem in prejeti odmerek epoetina.
In both studies, the mean percent improvement in PASI from baseline remained stable during the Randomized Treatment Withdrawal Phase for patients re-randomized to apremilast at Week 32 (Table 5).
V obeh študijah je pri bolnikih, ki so jih ponovno randomizirali na apremilast po 32 tednih, povprečno odstotno izboljšanje PASI od izhodišča v fazi odtegnitve randomiziranega zdravljenja ostalo stabilno (preglednica 5).
In both studies, the most common adverse reactions related to bleeding with edoxaban 60 mg based on adjudicated terms included cutaneous soft tissue haemorrhage (up to 5.9%) and epistaxis (up to 4.7%), while vaginal haemorrhage (9.0%) was the most common bleeding-related adverse reaction in Hokusai-VTE only.
V obeh študijah so najpogostejši neželeni učinki v zvezi s krvavitvami z edoksabanom 60 mg po strokovni presoji vključevali krvavitve v mehkih tkivih kože (do 5,9 %) in epistakso (do 4,7 %), medtem ko je bila vaginalna krvavitev (9,0 %) najpogostejši s krvavitvijo povezan neželeni učinek samo v študiji Hokusai-VTE.
In both studies, the patients had severe neutropenia for around 1.7 days during their first chemotherapy cycle, compared with around five to seven days when no stimulating factor is used.
V obeh študijah je huda nevtropenija pri bolnikih med prvim ciklom kemoterapije trajala 1,7 dni v primerjavi s približno pet do sedem dni, ko ni bil uporabljen noben spodbujajoči faktor.
In both studies, the primary endpoint was the proportion of patients who achieved PASI-75 at Week 16.
V obeh študijah je bil primarni končni opazovani dogodek delež bolnikov, ki so do 16. tedna dosegli PASI-75.
In both studies, the time it took for the patient’s symptoms to improve was shorter for patients taking Firazyr than for those taking tranexamic acid or placebo.
V obeh študijah je bil čas do izboljšanja bolnikovih simptomov krajši pri bolnikih, ki so jemali zdravilo Firazyr, kot pri tistih, ki so jemali traneksamično kislino ali placebo.
In both studies, there were more patients who received Mozobil that achieved the target number of stem cells and in whom the stems cells were successfully engrafted.
V obeh študijah je bilo pri več bolnikih, ki so prejemali zdravilo Mozobil in katerih matične celice so bile uspešno vcepljene, doseženo ciljno število matičnih celic.
In both studies, which were still ongoing at the time of Tagrisso’s initial evaluation, the medicine was not compared with any other treatment.
V nobeni od študij, ki sta v času ocenjevanja zdravila Tagrisso še potekali, zdravila niso primerjali z nobenim drugim zdravilom.
In both studies, which were still ongoing at the time of Zykadia’s evaluation, the medicine was not compared with any other treatment.
V teh dveh študijah, ki sta v času ocenjevanja zdravila Zykadia še potekali, zdravila niso primerjali z nobenim drugim zdravilom.
In both Study 1 and Study 2, patients randomised to receive placebo who were non-responders at Week 12 then crossed over to receive Cosentyx (either 150 mg or 300 mg) at Weeks 12, 13, 14, and 15, followed by the same dose every month starting at Week 16.
Tako v 1. kot v 2. študiji so bolniki, ki so bili sprva randomizirani na prejemanje placeba in po 12 tednih pri njih ni prišlo do odziva, prešli na prejemanje zdravila Cosentyx (bodisi odmerka 150 mg ali 300 mg), in sicer so ustrezen odmerek prejeli v tednih 12, 13, 14 in 15, nato pa enak odmerek enkrat na mesec z začetkom v tednu 16.
In both Study 3 and Study 4, patients randomised to Cosentyx received 150 mg or 300 mg doses at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Tako v 3. kot v 4. študiji so bolniki, ki so bili randomizirani na prejemanje zdravila Cosentyx, prejeli odmerke 150 mg oziroma 300 mg v tednih 0, 1, 2 in 3, nato pa enak odmerek enkrat na mesec z začetkom v tednu 4.
In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range ( 2.0).
V obeh kliničnih preskušanjih, Einstein DVT in Einstein PE, so kot primerjalno zdravilo uporabili kombinacijo enoksaparina, vsaj 5 dni, in antagonista vitamina K, dokler ni PČ/INR dosegel terapevtske vrednosti ( 2,0).
In both treatment arms, children aged 6-11 years had a numercally higher rate of confirmed hypoglycaemia than in the other age groups.
V obeh skupinah zdravljenja so pri otrocih, starih 6 – 11 let, poročali o številčno večjem deležu potrjene hipoglikemije kot v drugih starostnih skupinah.
In both treatment arms, children aged 6-11 years had a numerically higher rate of confirmed hypoglycaemia than in the other age groups.
V obeh skupinah zdravljenja so pri otrocih, starih 6 – 11 let, poročali o številčno večjem deležu potrjene hipoglikemije kot v drugih starostnih skupinah.
In both treatment arms, patients with cirrhosis were at a higher risk to experience Grade 3-4 thrombocytopenia compared with non cirrhotic patients.
V obeh skupinah so imeli bolniki s cirozo, v primerjavi z bolniki brez ciroze, večje tveganje za pojav trombocitopenije 3. do 4. stopnje.
In both treatment arms, these chemonaive patients were fully supplemented with folic acid and vitamin B12.
V obeh vejah zdravljenja so bolniki, ki pred tem še niso prejeli kemoterapije, prejemali dopolnilno folno kislino in vitamin B12
In both trials, Betaferon showed a reduction in the number (30%) of clinical relapses.
V obeh študijah so ugotovili zmanjšanje števila (30 %) kliničnih recidivov pri uporabi zdravila Betaferon.
In both trials, Extavia showed a reduction in the number (30%) of clinical relapses.
V obeh študijah so pri uporabi zdravila Extavia ugotovili zmanjšanje števila (30 %) kliničnih recidivov.
In both trials, most cases of hand-foot skin reaction in patients treated with Stivarga appeared during the first cycle of treatment and were mild to moderate in severity (Grades 1 and 2: 28.6%, CRC and 44.7%, GIST).
V obeh preskušanjih se je večina kožnih reakcij na dlaneh in podplatih pri bolnikih, zdravljenih z zdravilom Stivarga, pojavila v prvem ciklu zdravljenja in so bile blage do zmerne (stopnje 1 in 2: 28,6 % pri bolnikih s kolorektalnim rakom in 44,7 % pri bolnikih z
In both trials, most cases of hypertension in patients treated with Stivarga appeared during the first cycle of treatment and were mild to moderate in severity (Grades 1 and 2: 22.8%, CRC and 31.1%, GIST).
V obeh preskušanjih se je večina primerov hipertenzije pri bolnikih, zdravljenih z zdravilom Stivarga, pojavila v prvem ciklu zdravljenja, in so bili blagi do zmerni (stopnje 1 in 2: 22,8 % pri bolnikih z metastatskim kolorektalnim rakom in 31,1 % pri bolnikih z GIST).
In both trials, the overall incidence of hand-foot skin reaction (78.4%, CRC and 88.2%, GIST) was higher in Stivarga-treated Asian patients compared to other ethnicities.
V obeh kliničnih preskušanjih je bila celokupna incidenca kožnih reakcij na dlaneh in podplatih (78,4 % pri bolnikih s kolorektalnim rakom in 88,2 % pri bolnikih z GIST) večja pri bolnikih azijske rase, ki so bili zdravljeni z zdravilom Stivarga, v primerjavi z drugimi etničnimi skupinami bolnikov.
In both trials, the primary endpoint was progression-free survival (PFS) defined by MRI scans or neurological worsening.
V obeh preskušanjih je bila primarna končna točka preskušanja čas preživetja brez napredovanja bolezni (PFS – »progression-free survival«), ugotovljen na podlagi NMR posnetkov, ali poslabšanje nevrološkega stanja bolnika.
In both trials, the primary endpoint was progression-free survival (PFS) defined by MRI scans or neurological worsening.
V obeh preskušanjih je bila primarna končna točka preskušanja čas preživetja brez napredovanja bolezni (PFS – »progression-free survival«), ugotovljen na podlagi NMR posnetkov, ali poslabšanje nevrološkega statusa bolnika.
In both trials, treatment with lumacaftor/ivacaftor resulted in a statistically significant improvement in ppFEV1 (Table 3).
V obeh preskušanjih je zdravljenje z lumakaftorjem/ivakaftorjem povzročilo statistično signifikantno izboljšanje ppFEV1 (preglednica 3).
In both UNITI-1 and UNITI-2, a significantly greater proportion of patients were in clinical response and remission in the ustekinumab treated group compared to placebo (Table 3).
Preglednica 4: Povzetek rezultatov kliničnega odziva v 1. študiji psoriaze (PHOENIX 1) in v 2. študiji psoriaze (PHOENIX 2)
In Brazil, Synflorix was introduced into the national immunisation programme (NIP) using a 3+1 schedule in infants (2, 4, 6 months of age and a booster dose at 12 months) with a catch-up campaign in children up to 2 years of age.
Na Finskem je bilo cepivo Synflorix vključeno v NPC po shemi 2+1 pri dojenčkih (v starosti 3 in 5 mesecev in obnovitveni odmerek pri 12 mesecih), brez možnosti naknadne priključitve programu cepljenja.
In BRCA-deficient in vivo models, olaparib given after platinum treatment resulted in a delay in tumour progression and an increase in overall survival compared to platinum treatment alone.
V modelih pomanjkanja BRCA in vivo je olaparib, uporabljen po zdravljenju na osnovi platine, upočasnil napredovanje tumorja in je podaljšal celokupno preživetje v primerjavi s samostojnim zdravljenjem na osnovi platine.
In BRCA-mutated patients (n=136) there was a statistically significant improvement in PFS, TFST, and TSST.
Pri bolnicah z mutacijo gena BRCA (n = 136) so ugotovili statistično značilno izboljšanje PFS, TFST in TSST.
In breast-feeding mothers given Gardasil or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable between the vaccination and the placebo groups.
Med potekom cepljenja v kliničnih preskušanjih, v katerih so doječe matere prejele cepivo Gardasil ali placebo, je bil odstotek neželenih učinkov pri materi in dojenem otroku v skupini, ki je prejela cepivo, primerljiv z odstotkom v skupini, ki je prejela placebo.
In breast-feeding mothers given Silgard or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable between the vaccination and the placebo groups.
Med potekom cepljenja v kliničnih preskušanjih, v katerih so doječe matere prejele cepivo Silgard ali placebo, je bil odstotek neželenih učinkov pri materi in dojenem otroku v skupini, ki je prejela cepivo, primerljiv z odstotkom v skupini, ki je prejela placebo.
In BRIGHTER, ranibizumab 0.5 mg with adjunctive laser therapy demonstrated non-inferiority versus ranibizumab monotherapy from baseline to Month 24 (95% CI -2.8, 1.4).
V študiji BRIGHTER je bilo zdravljenje z ranibizumabom 0,5 mg z dodatnim laserskim zdravljenjem neinferiorno v primerjavi z zdravljenjem z ranibizumabom v monoterapiji v času od izhodišča do konca 24. meseca (95-odstotni IZ: -2,8, 1,4).
In BRVO/CRVO clinical studies, cataract was reported more frequently in patients with phakic lens receiving a second injection (see SmPC section 4.8).
V kliničnih študijah BRVO/CRVO so o katarakti pogosteje poročali pri bolnikih s fakično lečo, ki so prejeli drugo injiciranje (glejte poglavje 4.8 v Povzetku glavnih značilnosti zdravila).
In cancer of the cervix, one main study involving 452 patients with advanced persistent, recurrent or metastatic disease was carried out.
V zvezi z rakom materničnega vratu je bila izvedena ena glavna študija, v katero je bilo vključenih 452 bolnic z napredovalo kronično, ponavljajočo se ali metastatsko boleznijo.
in cancer patients
pri bolnikih z rakom
In cancer patients receiving chemotherapy, fewer of the patients treated with Aranesp needed a blood transfusion than those given placebo.
Pri rakavih bolnikih, ki so prejemali kemoterapijo, je transfuzijo potrebovalo manj bolnikov, ki so bili zdravljeni z zdravilom Aranesp, kot tisti, ki so prejemali placebo.
In cancer patients receiving chemotherapy, fewer patients treated with Nespo needed a blood transfusion compared with those given placebo.
Pri bolnikih z rakom, ki so prejemali kemoterapijo, je transfuzijo krvi potrebovalo manj bolnikov, zdravljenih z zdravilom Nespo, v primerjavi s tistimi bolniki, ki so prejemali placebo.
In cancer patients receiving chemotherapy, the 2-3 week delay between erythropoietin administration and the appearance of erythropoietin-induced red cells should be taken into account when assessing if Retacrit therapy is appropriate (patient at risk of being transfused).
Pri rakavih bolnikih na kemoterapiji je treba pri vprašanju, ali je zdravljenje z zdravilom Retacrit primerno (bolniki s povečanim tveganjem pri transfuzijah), upoštevati 2-3 tedenski zamik med začetkom dajanja eritropoetina in pojavom eritrocitov, ki jih eritropoetin inducira.
In cancer patients, the pharmacokinetic profile of Filgrastim ratiopharm and the reference product was comparable after single and repeated subcutaneous administration.
Pri bolnikih z rakom sta bila farmakokinetična profila zdravila Filgrastim ratiopharm in referenčnega zdravila primerljiva po enkratnem in ponavljajočem odmerku, ki so ga bolniki prejeli po subkutani poti.
In cancer that is recurrent (when it has come back after previous treatment) or metastatic, Erbitux is used with a ‘platinum-based’ anticancer medicine combination (including medicines such as cisplatin or carboplatin).
Pri ponavljajočem (ki se ponovi po predhodnem zdravljenju) ali metastatskem raku se zdravilo Erbitux uporablja v kombinaciji z zdravili za zdravljenje raka na osnovi platine (vključno z zdravili, kot je cisplatin ali karboplatin).
In CAPS and Still’s disease, treatment with Ilaris should be started and supervised by a specialist doctor experienced in diagnosing and treating these conditions.
Pri obolenjih CAPS in Stillovi bolezni mora zdravljenje z zdravilom Ilaris uvesti in nadzirati zdravnik specialist, ki ima izkušnje z njihovim diagnosticiranjem in zdravljenjem.
In CAPS patients approximate dose linearity with a slight tendency to higher than proportional increase has been noted.
Pri bolnikih s CAPS so opazili približno premosorazmernost z odmerkom z rahlo nagnjenostjo k več kot sorazmernemu povečanju.
In CAPS, Ilaris was more effective than placebo.
Pri obolenjih CAPS je bilo zdravilo Ilaris učinkovitejše od placeba.
In CAPS, the recommended dose depends on the patient’s bodyweight and age and is given as an injection under the skin every eight weeks.
Priporočeni odmerek pri obolenjih CAPS je odvisen od bolnikove telesne mase in starosti ter se daje vsakih osem tednov z injiciranjem pod kožo.
In CAPS, you should not inject Ilaris earlier than 8 weeks after the last dose, unless your doctor tells you to.
Če imate katerega od sindromov CAPS, si zdravila Ilaris ne smete injicirati prej kot 8 tednov po zadnjem odmerku, razen če vam je to naročil zdravnik.
In carcinogenicity studies, nevirapine induces hepatic tumours in rats and mice.
Pri študijah vpliva na sposobnost razmnoževanja so odkrili škodljive učinke na plodnost pri podganah.
In cardboard boxes: Lyophilisate: vial (glass); Solvent: vial (glass)
Liofilizat: viala (steklena) Topilo: viala (steklena)
In cardboard boxes: Lyophilisate: vial (glass); Solvent: vial (PET)
Liofilizat: viala (steklena) Topilo: viala (PET)
In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of Flixabi (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1 hour.
Pri skrbno izbranih odraslih bolnikih, ki so dobro prenesli vsaj 3 začetne 2-urne infuzije zdravila Flixabi (uvajalna faza zdravljenja) in so trenutno na vzdrževalnem zdravljenju, lahko razmislite o skrajšanju naslednjih infuzij, vendar ne na manj kot 1 uro.
In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of Inflectra (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1 hour.
Pri skrbno izbranih odraslih bolnikih, ki so dobro prenesli vsaj 3 začetne 2-urne infuzije zdravila Inflectra (uvajalna faza zdravljenja) in so trenutno na vzdrževalnem zdravljenju, lahko razmislite o skrajšanju naslednjih infuzij, vendar ne na manj kot 1 uro.
In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of Remicade (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1 hour.
Pri skrbno izbranih odraslih bolnikih, ki so dobro prenesli vsaj 3 začetne 2-urne infuzije zdravila Remicade (uvajalna faza zdravljenja) in so trenutno na vzdrževalnem zdravljenju, lahko razmislite o skrajšanju naslednjih infuzij, vendar ne na manj kot 1 uro.